Thrombocytopenia 4 (THC4): Six novel families with mutations of the cytochrome c gene
Antonio Marzollo,Stefania Zampieri,Serena Barozzi,Muhammad Abrar Yousaf,Jade Quartararo,Daniela De Rocco,Michela Faleschini,Caterina Marconi,Camilla Ceccatelli Berti,Valeria Bozzi,Giovanna Russo,Paola Giordano,Paola Goffrini,Silvia Bresolin,Annalisa Pastore,Anna Savoia,Alessandro Pecci
DOI: https://doi.org/10.1111/bjh.19567
2024-06-01
British Journal of Haematology
Abstract:In the largest cohort study to date, comprising 22 Thrombocytopenia 4 (THC4) patients from six families, five heterozygous missense CYCS variants, Gly42Ser, Tyr49His, Ala52Thr, Arg92Gly, and Leu99Val, were identified. Bioinformatics analysis classified these variants as pathogenic, affecting structure and function of the protein. Functional validation using a yeast model demonstrated that the Ala52Thr and Arg92Gly mutations impair oxidative growth and respiratory activities, confirming their adverse effects. This study also described the clinical phenotypes of this cohort, characterized by mild‐to‐moderate thrombocytopenia with normal platelet size and function, and minimal to no bleeding risk. This study establishes a potential correlation between specific regions of CYCS affected by mutations and the severity of thrombocytopenia, underscoring the variant‐specific functional impairments of CYCS. Summary Thrombocytopenia 4 (THC4) is an autosomal‐dominant thrombocytopenia caused by mutations in CYCS, the gene encoding cytochrome c (CYCS), a small haeme protein essential for electron transport in mitochondria and cell apoptosis. THC4 is considered an extremely rare condition since only a few patients have been reported so far. These subjects presented mild thrombocytopenia and no or mild bleeding tendency. In this study, we describe six Italian families with five different heterozygous missense CYCS variants: p.Gly42Ser and p.Tyr49His previously associated with THC4, and three novel variants (p.Ala52Thr, p.Arg92Gly, and p.Leu99Val), which have been classified as pathogenic by bioinformatics and segregation analyses. Moreover, we supported functional effects of p.Ala52Thr and p.Arg92Gly on oxidative growth and respiratory activity in a yeast model. The clinical characterization of the 22 affected individuals, the largest series of THC4 patients ever reported, showed that this disorder is characterized by mild‐to‐moderate thrombocytopenia, normal platelet size, and function, low risk of bleeding, and no additional clinical phenotypes associated with reduced platelet count. Finally, we describe a significant correlation between the region of CYCS affected by mutations and the extent of thrombocytopenia, which could reflect different degrees of impairment of CYCS functions caused by different pathogenetic variants.
hematology